Antibacterial activity of cefpodoxime in vitro

Yung Ching Liu, Wen Kuei Huang, Deh L. Cheng

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Cefpodoxime proxetil is a new orally administered prodrug which is absorbed and de-esterified by the intestinal mucosa to release the third-generation cephalosporin, cefpodoxime, and which is undergoing in vitro and in vivo evaluations. Using the standard agar dilution method, we compared the in vitro activity of this drug with other oral cephalosporins and quinolones against 637 recent clinical isolates from Kaohsiung Veterans General Hospital in Taiwan. Against Escherichia coli and Klebsiella pneumoniae, cefpodoxime showed excellent activity, inhibiting over 90% of these isolates at 1 mg/l. Like other oral drugs of its class, it had little activity against Pseudomonas aeruginosa and Acinetobacter spp. Against Haemophilus influenzae, irrespective of P-lactamase production, its activity was similar to comparative drugs. Against methicillin-susceptible Staphylococcus aureus, cefpodoxime showed moderate activity, inhibiting 90% of these isolates at 4 mg/l, whereas it was inactive against methicillin-resistant S. aureus. However, all cephalosporins have shown little in vivo activity against methicillin-resistant S. aureus regardless of in vitro results. Cefpodoxime was inactive against Entesococcus spp. Against other streptococci, its activity was similar to other oral cephalosporins and quinolones tested. The results of this in vitro study indicated that oral administration of cefpodoxime should be an ideal agent in the empirical outpatient treatment for community-acquired cutaneous, respiratory and urinary tract infections.

Original languageEnglish
Pages (from-to)21-26
Number of pages6
JournalChemotherapy
Volume43
Issue number1
Publication statusPublished - Jan 1997
Externally publishedYes

Fingerprint

cefpodoxime
Cephalosporins
cefpodoxime proxetil
Quinolones
Methicillin-Resistant Staphylococcus aureus
Pharmaceutical Preparations
Veterans Hospitals
Acinetobacter
Methicillin
Haemophilus influenzae
Prodrugs
Klebsiella pneumoniae
Intestinal Mucosa
Streptococcus
Taiwan
Urinary Tract Infections
General Hospitals
Respiratory Tract Infections
Pseudomonas aeruginosa
Agar

Keywords

  • Cefpodoxime
  • Cephalosporin
  • In vitro activity

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Liu, Y. C., Huang, W. K., & Cheng, D. L. (1997). Antibacterial activity of cefpodoxime in vitro. Chemotherapy, 43(1), 21-26.

Antibacterial activity of cefpodoxime in vitro. / Liu, Yung Ching; Huang, Wen Kuei; Cheng, Deh L.

In: Chemotherapy, Vol. 43, No. 1, 01.1997, p. 21-26.

Research output: Contribution to journalArticle

Liu, YC, Huang, WK & Cheng, DL 1997, 'Antibacterial activity of cefpodoxime in vitro', Chemotherapy, vol. 43, no. 1, pp. 21-26.
Liu YC, Huang WK, Cheng DL. Antibacterial activity of cefpodoxime in vitro. Chemotherapy. 1997 Jan;43(1):21-26.
Liu, Yung Ching ; Huang, Wen Kuei ; Cheng, Deh L. / Antibacterial activity of cefpodoxime in vitro. In: Chemotherapy. 1997 ; Vol. 43, No. 1. pp. 21-26.
@article{eaac8d308d9e47aea7517b156f44f592,
title = "Antibacterial activity of cefpodoxime in vitro",
abstract = "Cefpodoxime proxetil is a new orally administered prodrug which is absorbed and de-esterified by the intestinal mucosa to release the third-generation cephalosporin, cefpodoxime, and which is undergoing in vitro and in vivo evaluations. Using the standard agar dilution method, we compared the in vitro activity of this drug with other oral cephalosporins and quinolones against 637 recent clinical isolates from Kaohsiung Veterans General Hospital in Taiwan. Against Escherichia coli and Klebsiella pneumoniae, cefpodoxime showed excellent activity, inhibiting over 90{\%} of these isolates at 1 mg/l. Like other oral drugs of its class, it had little activity against Pseudomonas aeruginosa and Acinetobacter spp. Against Haemophilus influenzae, irrespective of P-lactamase production, its activity was similar to comparative drugs. Against methicillin-susceptible Staphylococcus aureus, cefpodoxime showed moderate activity, inhibiting 90{\%} of these isolates at 4 mg/l, whereas it was inactive against methicillin-resistant S. aureus. However, all cephalosporins have shown little in vivo activity against methicillin-resistant S. aureus regardless of in vitro results. Cefpodoxime was inactive against Entesococcus spp. Against other streptococci, its activity was similar to other oral cephalosporins and quinolones tested. The results of this in vitro study indicated that oral administration of cefpodoxime should be an ideal agent in the empirical outpatient treatment for community-acquired cutaneous, respiratory and urinary tract infections.",
keywords = "Cefpodoxime, Cephalosporin, In vitro activity",
author = "Liu, {Yung Ching} and Huang, {Wen Kuei} and Cheng, {Deh L.}",
year = "1997",
month = "1",
language = "English",
volume = "43",
pages = "21--26",
journal = "Chemotherapy",
issn = "0009-3157",
publisher = "S. Karger AG",
number = "1",

}

TY - JOUR

T1 - Antibacterial activity of cefpodoxime in vitro

AU - Liu, Yung Ching

AU - Huang, Wen Kuei

AU - Cheng, Deh L.

PY - 1997/1

Y1 - 1997/1

N2 - Cefpodoxime proxetil is a new orally administered prodrug which is absorbed and de-esterified by the intestinal mucosa to release the third-generation cephalosporin, cefpodoxime, and which is undergoing in vitro and in vivo evaluations. Using the standard agar dilution method, we compared the in vitro activity of this drug with other oral cephalosporins and quinolones against 637 recent clinical isolates from Kaohsiung Veterans General Hospital in Taiwan. Against Escherichia coli and Klebsiella pneumoniae, cefpodoxime showed excellent activity, inhibiting over 90% of these isolates at 1 mg/l. Like other oral drugs of its class, it had little activity against Pseudomonas aeruginosa and Acinetobacter spp. Against Haemophilus influenzae, irrespective of P-lactamase production, its activity was similar to comparative drugs. Against methicillin-susceptible Staphylococcus aureus, cefpodoxime showed moderate activity, inhibiting 90% of these isolates at 4 mg/l, whereas it was inactive against methicillin-resistant S. aureus. However, all cephalosporins have shown little in vivo activity against methicillin-resistant S. aureus regardless of in vitro results. Cefpodoxime was inactive against Entesococcus spp. Against other streptococci, its activity was similar to other oral cephalosporins and quinolones tested. The results of this in vitro study indicated that oral administration of cefpodoxime should be an ideal agent in the empirical outpatient treatment for community-acquired cutaneous, respiratory and urinary tract infections.

AB - Cefpodoxime proxetil is a new orally administered prodrug which is absorbed and de-esterified by the intestinal mucosa to release the third-generation cephalosporin, cefpodoxime, and which is undergoing in vitro and in vivo evaluations. Using the standard agar dilution method, we compared the in vitro activity of this drug with other oral cephalosporins and quinolones against 637 recent clinical isolates from Kaohsiung Veterans General Hospital in Taiwan. Against Escherichia coli and Klebsiella pneumoniae, cefpodoxime showed excellent activity, inhibiting over 90% of these isolates at 1 mg/l. Like other oral drugs of its class, it had little activity against Pseudomonas aeruginosa and Acinetobacter spp. Against Haemophilus influenzae, irrespective of P-lactamase production, its activity was similar to comparative drugs. Against methicillin-susceptible Staphylococcus aureus, cefpodoxime showed moderate activity, inhibiting 90% of these isolates at 4 mg/l, whereas it was inactive against methicillin-resistant S. aureus. However, all cephalosporins have shown little in vivo activity against methicillin-resistant S. aureus regardless of in vitro results. Cefpodoxime was inactive against Entesococcus spp. Against other streptococci, its activity was similar to other oral cephalosporins and quinolones tested. The results of this in vitro study indicated that oral administration of cefpodoxime should be an ideal agent in the empirical outpatient treatment for community-acquired cutaneous, respiratory and urinary tract infections.

KW - Cefpodoxime

KW - Cephalosporin

KW - In vitro activity

UR - http://www.scopus.com/inward/record.url?scp=0031031152&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031031152&partnerID=8YFLogxK

M3 - Article

VL - 43

SP - 21

EP - 26

JO - Chemotherapy

JF - Chemotherapy

SN - 0009-3157

IS - 1

ER -